tegafur has been researched along with deoxycytidine in 502 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 18 (3.59) | 18.2507 |
2000's | 150 (29.88) | 29.6817 |
2010's | 308 (61.35) | 24.3611 |
2020's | 26 (5.18) | 2.80 |
Authors | Studies |
---|---|
Taguchi, T | 2 |
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
McCann, J | 1 |
Punt, CJ | 1 |
Bunnell, CA; Winer, EP | 1 |
Ajani, JA | 1 |
Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M | 2 |
Meropol, NJ | 1 |
González Barón, M | 1 |
Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH | 1 |
Arlauskas, P; Ibrahim, D; Philip, PA; Shields, A; Zalupski, M | 1 |
Lamont, EB; Schilsky, RL | 1 |
Adjei, AA | 1 |
Macdonald, JS | 1 |
Cao, S; Rustum, YM | 1 |
Bekradda, M; Cvitkovic, E | 1 |
Adenis, A; Conroy, T; Paillot, B | 1 |
Damjanov, N; Meropol, NJ | 1 |
Hoff, PM; Pazdur, R; Royce, ME | 2 |
Peeters, M; Van Cutsem, E | 1 |
Lewis, NL; Meropol, NJ | 1 |
Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L | 1 |
Maeda, Y; Sasaki, T | 1 |
Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
de Bono, JS; Twelves, CJ | 1 |
Cunningham, D; James, RD | 1 |
Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z | 1 |
Coleman, R; Cunningham, D | 1 |
Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H | 1 |
Aguayo, A; Patt, YZ | 1 |
Reimer, P; Rückle-Lanz, H | 1 |
Lokich, J | 1 |
Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K | 1 |
Croockewit, AJ; de Boer, JE; Koopmans, PP; van Loenhout, JW | 1 |
Aabo, K; Adimi, P; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E | 1 |
Malet-Martino, M; Martino, R | 1 |
Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE | 1 |
Eng, C; Kindler, HL; Schilsky, RL | 1 |
Mayor, S | 1 |
Hoff, PM | 1 |
Porschen, R | 1 |
Hitsuda, Y; Kawasaki, Y; Koshohbu, T; Matsumoto, S; Nakatani, S; Shimizu, E; Yasuda, K | 1 |
Maeda, Y; Sasaki, E; Sasaki, T | 1 |
Hosokawa, A | 1 |
Doi, T; Ohtsu, A | 1 |
Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S | 1 |
Ahn, JH; Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JS; Lee, K | 1 |
Cats, A | 1 |
Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K | 1 |
Folprecht, G; Köhne, CH | 1 |
Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY | 1 |
Fujihara, M; Fujita, M; Furukawa, Y; Hattori, Y; Ishii, Y; Kuniki, H; Matsumoto, N; Yajima, T; Yamamoto, M; Yamaoka, Y | 1 |
Ferrero, JM; François, E; Milano, G | 1 |
Rustum, YM | 1 |
Scheithauer, W | 1 |
Baba, Y; Ishikawa, T; Kamimura, T; Mizuno, K; Oota, H; Watanabe, K; Yoshida, T | 1 |
Dono, K; Hashimoto, K; Kubota, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, H; Umeshita, K; Yamamoto, S | 1 |
Amano, A; Masaki, T; Miyakawa, K; Ohkawa, S; Tarao, K; Ueno, M | 1 |
Abe, N; Atomi, Y; Sugiyama, M | 1 |
Ishihara, T; Kato, H; Kobayashi, A; Nakamura, K; Saisho, H; Sudo, K; Tadenuma, H; Yamaguchi, T | 1 |
Fujioka, A; Fukushima, M; Ikeda, K; Kitazato, K; Nakagawa, F; Ohshimo, H; Okabe, H; Takechi, T | 1 |
Masuda, N; Yanase, N; Yokoba, M | 1 |
Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S | 1 |
Araki, J; Ichinose, Y; Inoue, Y; Itoh, K; Iwamoto, N; Semba, H; Seto, T; Tamanoi, M; Tanaka, F; Yamamoto, H | 1 |
Fujii, M; Goubaru, M; Makino, Y; Ogata, M; Ohta, T; Tanaka, S | 1 |
Amano, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 1 |
Furuse, J; Ikeda, M; Ishiguro, Y; Ishii, H; Matsubara, J; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H | 1 |
Barón, MG; Casado, E; Castañón, C; Castro, J; Cruz, M; Feliu, J; Fonseca, E; Jara, C; Jaráiz, AR; León, A; Lomas, M; Sáenz, JG | 1 |
Funakoshi, A; Sumii, T | 1 |
Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 2 |
Goyle, S; Maraveyas, A | 1 |
Von Hoff, DD | 1 |
Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
Fujii, T; Habiro, A; Izawa, T; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakano, Y; Okumura, T; Osanai, M; Tanno, S; Yanagawa, N | 1 |
Abad, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Tabernero, J | 1 |
Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T | 1 |
Cowan, J; Kaltenthaler, E; Marples, M; Orr, B; Seymour, MT; Ward, SE | 1 |
Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, S; Tsujie, M; Umeshita, K | 1 |
Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
Machida, H; Suzuki, K; Toda, H; Ushida, S | 1 |
Boku, N; Fukutomi, A; Yoshino, T | 1 |
Aikou, T; Kitazono, M; Kubo, F; Maemura, K; Noma, H; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
Hanada, M; Noguchi, T; Yamaoka, T | 1 |
Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
El-Rayes, BF; LoRusso, P; Manza, SG; Philip, PA; Shields, AF; Zalupski, M | 1 |
Almond, J; Ralston, S | 1 |
Kim, R; Saif, MW | 1 |
Motoo, Y | 1 |
Fukushima, M; Maruyama, R; Nio, Y; Toga, T | 1 |
Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
Murakami, S; Yamamoto, Y | 1 |
Baehring, JM; Fulbright, RK | 1 |
Ito, H; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Sawada, S; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
Doi, T; Fujimi, A; Izumi, K; Kanisawa, Y; Kikuchi, S; Kitahara, T; Ohta, H; Okuda, T; Sato, Y | 1 |
Ajani, JA; Cen, P | 1 |
Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Saisho, H; Sato, T; Tanaka, K; Yamao, K; Yonemoto, N | 1 |
Ahn, JJ; Baek, JH; Cha, HJ; Jegal, Y; Jeong, AK; Jung, JP; Kim, H; Kim, JW; Kwon, WJ; Min, YJ; Noh, YJ; Park, CR; Park, JH; Seo, KW; Shin, JK; Shin, SJ | 1 |
Geboes, K; Van Cutsem, E | 1 |
Morizane, C | 1 |
Boku, N; Fukutomi, A; Kinoshita, T; Kondo, S; Maeda, A; Nagino, M; Uesaka, K | 1 |
Cascinu, S | 1 |
Chiba, T; Doi, R; Fukushima, M; Ishiguro, H; Kami, K; Kanai, M; Kawaguchi, Y; Kitano, T; Matsumoto, S; Misawa, A; Nishimura, T; Yamauchi, J; Yanagihara, K; Yasuda, H; Yazumi, S; Yoshikawa, K | 1 |
Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
Han, CJ | 1 |
Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H | 1 |
Arita, Y; Eriguchi, N; Funakoshi, A; Igarashi, H; Ito, T; Miyahara, T; Mizumoto, K; Muranaka, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H | 1 |
Akiyama, S; Fukushima, M; Oka, T; Ooyama, A; Yamamoto, M; Zhao, HY | 1 |
Furuse, J; Ioka, T; Ishii, H; Ito, Y; Okusaka, T; Shibuya, K; Shinchi, H; Yamada, S | 1 |
Kuwahara, A; Masuda, T | 1 |
Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
Aoki, H; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
Barone, C; Pozzo, C | 1 |
Fujimori, N; Fujimoto, C; Funakoshi, A; Maruyama, Y; Niina, Y; Sumii, T | 1 |
Fujimoto, K; Hara, T; Kurahashi, T; Muraki, Y; Nagata, M; Yamashita, Y; Yasuda, Y | 1 |
Hirata, K; Kawasaki, H; Kukita, K; Mizushima, Y | 1 |
Baek, JH; Chang, HM; Kang, HJ; Kang, WK; Kang, YK; Kim, JG; Kim, TW; Lee, JL; Lee, KH; Min, YJ; Park, SR; Ryoo, BY; Ryu, MH; Shin, DB; Zang, DY | 1 |
Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
Chohnabayashi, N; Horinouchi, H; Nishimura, N; Ono, H; Sugiura, R; Uchiyama, N; Ueda, H | 1 |
Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Tsuchiya, T; Utsugi, M; Yanagitani, N | 1 |
Hatake, K; Ito, Y; Iwase, T; Osaki, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
Bekaii-Saab, T; Haghighat, P | 1 |
Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O | 1 |
Cho, GJ; Choi, YJ; Chung, JS; Kim, GH; Seol, YM; Shin, HJ; Song, GA; Song, MK | 1 |
Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP | 1 |
Bae, SH; Eun, JR; Hyun, MS; Jang, BI; Kim, MK; Kim, TN; Lee, KH; Lee, SA; Ryoo, HM | 1 |
Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, MJ; Kim, TY; Lee, SH; Oh, DY | 1 |
Aoki, T; Hamada, H; Kenno, S; Oba, G; Okuda, K; Shimada, S; Shimokuni, T; Takada, J | 1 |
Iida, M; Tokairin, Y; Yamazaki, S | 1 |
Jeong, CY; Ju, JH; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Kim, TH; Lee, GW | 1 |
Hirohata, S; Horita, K; Niki, T; Nishisaki, H; Tsuda, M; Yamamoto, Y | 1 |
Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
Abe, T; Ikeda, K; Koeda, K; Minakawa, Y; Nitta, H; Obuchi, T; Otsuka, K; Sasaki, A; Shimooki, O; Wakabayashi, G | 1 |
Endo, M; Hasegawa, I; Kato, A; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Tanaka, Y; Tokuda, Y | 1 |
Amano, A; Masaki, T; Miyakawa, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
Bang, YJ; Cha, Y; Choi, IK; Choi, IS; Kim, CD; Kim, JH; Kim, JS; Kim, YH; Oh, DY; Oh, SC; Yoon, SY | 1 |
Fushida, S; Kimura, H; Mukawa, A | 1 |
Chen, XQ; He, YJ; Li, YH; Pan, ZZ; Qiu, MZ; Ruan, DY; Teng, KY; Wan, DS; Xu, RH | 1 |
Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H | 1 |
Ikeda, M; Morizane, C; Okusaka, T; Seki, Y; Ueno, H | 1 |
Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I | 1 |
Alkis, N; Aslan, UY; Benekli, M; Buyukberber, S; Camci, C; Celenkoglu, G; Coskun, U; Er, O; Ozkan, M; Ozturk, B; Sevinc, A; Tokluoglu, S; Uner, A; Yildiz, R | 1 |
Cho, YB; Chun, HK; Kim, HC; Lee, WY; Yun, HR; Yun, SH | 1 |
Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
Teng, KY; Xu, RH | 1 |
Chiba, A; Fujii, T; Habiro, A; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakamura, K; Nakano, Y; Nishikawa, T; Okumura, T; Sasajima, J; Sugiyama, Y; Tanno, S | 1 |
Fukada, I; Ikeda, H; Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
Abe, K; Kanno, Y; Katsushima, F; Monoe, K; Ohira, H; Takahashi, A; Wakatsuki, T; Yokokawa, J | 1 |
Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawabe, T; Kawakubo, K; Kogure, H; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
Furuse, J; Ikeda, M; Ishii, H; Kawashima, M; Kinoshita, T; Mitsunaga, S; Nakachi, K; Shimizu, S | 1 |
Doki, Y; Eguchi, H; Hoshino, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K | 1 |
Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T | 1 |
Funada, N; Honda, G; Kurata, M; Tokashiki, T; Tsuruta, K; Watanabe, F | 1 |
Fukunaga, M; Furukawa, H; Ikeda, H; Mabuchi, E; Matsumura, T; Miwa, H; Ohzato, H; Ota, K; Yamamoto, T | 1 |
Nakayama, T; Noguchi, S | 1 |
Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S | 1 |
Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N | 1 |
Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Sakamoto, T; Taku, K; Todaka, A; Tomita, H; Yamazaki, K; Yasui, H | 1 |
Komori, E; Nogami, H; Ogino, A; Sawada, S; Segawa, Y; Shinkai, T; Suehiro, H; Yamashita, M | 1 |
Denda, T; Hara, T; Ishihara, T; Nakamura, K; Sudo, K; Yamaguchi, T; Yokosuka, O | 1 |
Imawari, M; Ito, N; Kiuchi, Y; Kobayashi, M; Kogo, M; Konishi, K; Kurihara, T; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Tsujino, T | 1 |
Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
Miyagawa, K; Sagara, Y; Yamaoka, N; Yata, Y | 1 |
Kameda, R; Kobayashi, S; Miyagawa, K; Morinaga, S; Okawa, S; Ueno, M | 1 |
Fujii, Y; Iino, Y; Isayama, H; Kamimura, H; Kihara, K | 1 |
Altman, RB; Carrillo, MW; Klein, TE; Marsh, S; McLeod, HL; Thorn, CF | 1 |
Araki, H; Denda, T; Hara, T; Hatano, K; Imagumbai, T; Ishihara, T; Ito, H; Kawakami, H; Nakamura, K; Sakai, M; Sudo, K; Tawada, K; Uno, T; Yamaguchi, T; Yokosuka, O | 1 |
Fukuda, H; Furuse, J; Ishii, H; Morizane, C; Nakamura, K; Okusaka, T; Takashima, A | 1 |
Gocho, T; Hirohara, S; Iida, T; Misawa, T; Sakamoto, T; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
Arakawa, A; Hisama, S; Kimura, M; Matsushita, H; Nishimura, T; Okamura, S; Saitoh, S; Shimokawa, Y; Tanaka, Y; Toyama, H | 1 |
Akiyama, N; Ayata, S; Maruyama, Y; Tsukada, Y | 1 |
Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K | 1 |
Fukui, H; Kou, C; Matsumoto, M; Matsumoto, T | 1 |
Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K | 1 |
Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H | 1 |
Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T | 1 |
Boot, H; Cats, A; Deenen, MJ; Schellens, JH; Terpstra, WE | 1 |
Inoue, H; Murakami, M; Nishizaki, T; Shimabukuro, R; Shiraishi, T; Takahashi, I; Yano, H | 1 |
Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N | 1 |
Amano, R; Doi, Y; Hirakawa, K; Iwauchi, T; Nakamoto, K; Ohira, G; Ohira, M; Yamada, N | 1 |
Akagi, K; Dono, K; Fujino, S; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Kitahara, T; Miyake, M; Munakata, K; Nagai, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yanagawa, T | 1 |
Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T | 1 |
Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E | 1 |
Dowaki, S; Hirabayashi, K; Imaizumi, T; Makuuchi, H; Matsuyama, M; Okada, K; Tobita, K; Yazawa, N | 1 |
Hatata, T; Ikeguchi, M; Kondo, A; Naka, T; Takaya, S; Taniguchi, K | 1 |
Hatano, E; Ikeda, K; Kamo, N; Mitsuyoshi, H; Mori, A; Nitta, T; Uemoto, S | 1 |
Fukuoka, J; Hosokawa, A; Ishizawa, S; Itaya, Y; Kajiura, S; Kawai, K; Minemura, M; Nakayama, Y; Nishimizu, T; Sawasaki, T; Shimizu, S; Sugiyama, T; Tajiri, K; Takahara, T; Tokimitsu, Y; Yamawaki, H; Yanagisawa, A; Yasumura, S | 1 |
Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C | 1 |
Doki, Y; Endo, W; Hasuike, Y; Masutani, S; Monden, M; Mori, M; Morimoto, T; Nakamori, S; Ozato, H; Shibata, T; Takeda, Y; Tohno, K | 1 |
Kenno, S; Kobayashi, T; Kuji, M; Tani, C; Yamamoto, Y | 1 |
Ajani, JA; Blum, M; Suzuki, A | 1 |
Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
Handa, K; Hatogai, K; Hibi, T; Higuchi, H; Iwasaki, E; Izumiya, M; Kishino, R; Maeda, N; Mizuki, A; Mukai, K; Nakazawa, A; Seki, E; Shimoyama, Y; Takaishi, H; Takita, M; Tsukada, N | 1 |
Giannini, OH; González, ME; González, P; Saldaña, B | 1 |
Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y | 1 |
Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
Murakami, Y; Sudo, T; Uemura, K | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM | 1 |
Furuse, J; Ikeda, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Shinichi, O; Suzuki, E; Ueno, H; Ueno, M; Yamaguchi, T | 1 |
Asagi, A; Hori, S; Iguchi, H; Ikeda, Y; Kajiwara, T; Matsumoto, T; Nadano, S; Nishina, T; Takeji, S | 1 |
Inoue, K; Kamata, M; Kitade, H; Kwon, AH; Matsui, Y; Ohe, C; Sakaida, N; Satoi, S; Tanigawa, N; Toyokawa, H; Uemura, Y; Yamamoto, T; Yanagimoto, H | 1 |
Bjerregaard, JK; Jensen, HA; Mortensen, MB; Nielsen, M; Pfeiffer, P | 1 |
Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
Ahn, JJ; Baek, JH; Cha, HJ; Jegal, Y; Jung, JP; Kim, H; Kim, JW; Kwon, WJ; Lee, YJ; Min, YJ; Noh, YJ; Oh, S; Park, CR; Park, JH; Ra, SW; Seo, KW | 1 |
Aoyagi, H; Hasegawa, K; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Takahata, T; Yoshida, T | 1 |
Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Kitasato, Y; Mikagi, K; Nakayama, M; Okabe, Y; Yasunaga, M; Yoshitomi, M | 1 |
Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Sanada, T; Wakabayashi, M | 1 |
Akagi, K; Dono, K; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Miyake, M; Nagai, K; Shimano, T; Shimizu, J | 1 |
Hasegawa, Y; Itou, N; Nishizuka, S; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
Kato, K | 1 |
Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D | 1 |
Iizawa, H; Kakizaki, Y; Motoi, F; Okada, T; Sakurai, N; Tamura, G; Unno, M; Yamamoto, K | 1 |
Chung, HC; Jeung, HC; Jung, I; Kim, GM; Kim, HS; Lee, KH; Nam, BH; Rha, SY | 1 |
Egawa, N; Hanada, K; Hijioka, S; Hirose, Y; Ikari, T; Ikeda, T; Ishii, H; Itoi, T; Kimura, Y; Maetani, I; Matsumura, Y; Mouri, H; Nakajima, T; Ohoka, S; Okabe, Y; Omuro, Y; Ozaka, M; Sofuni, A; Suyama, M; Tani, M; Watanabe, R | 1 |
Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
Chang, JS; Chung, Y; Koom, WS; Seong, J; Song, SY; Wang, ML; Yoon, HI | 1 |
Hashimoto, Y; Hiyama, E; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
Hirai, K; Katoh, R; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D | 1 |
Asanuma, F; Atsuda, K; Morimoto, Y; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoneyama, H | 1 |
Kondo, C; Matsuo, K; Mizota, A; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
Abe, S; Harada, M; Hiura, M; Kihara, Y; Miyagawa, K; Shimajiri, S; Taguchi, M; Yamamoto, M | 1 |
Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H | 1 |
Fukuoka, J; Hori, R; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Watanabe, T; Yoshioka, I | 1 |
Kondo, C; Matsuo, K; Muro, K; Niwa, Y; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T | 1 |
Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW | 1 |
Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY | 1 |
Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J | 1 |
Kobayashi, M; Kodera, Y; Morita, S; Sakamoto, J; Shitara, K; Tsuburaya, A; Yamaguchi, K; Yoshida, K; Yoshikawa, T; Yoshino, S | 1 |
Andou, T; Kameda, R; Kobayashi, S; Morinaga, S; Ohkawa, S; Ueno, M; Yamamoto, N | 1 |
Bernstine, H; Brenner, B; Goldberg, N; Gordon, N; Groshar, D; Idelevich, E; Kundel, Y; Morgenstern, S; Purim, O; Sulkes, A; Wasserberg, N | 1 |
Abe, T; Fujikawa, T; Kawashima, T; Maekawa, H; Shimoike, N; Shiraishi, K; Tada, S; Tanaka, A; Tanaka, H; Yoshimoto, Y | 1 |
Baek, JH; Cho, SH; Choi, YH; Chung, IJ; Hong, YS; Jeung, HC; Kang, HJ; Kim, BS; Kim, JS; Nam, SH; Oh, SC; Song, EK; Yang, SH; Yim, CY | 1 |
Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yamamoto, N | 1 |
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y | 1 |
Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
Grothey, A | 1 |
Adachi, T; Goto, A; Itoh, M; Kanno, S; Kondo, Y; Mitsuhashi, K; Shinomura, Y; Suzuki, T; Wakasugi, H; Yabana, T | 1 |
Hirashima, Y; Shirao, K | 1 |
Fujioka, M; Fukui, H; Kou, C | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K | 2 |
Beijnen, JH; Cats, A; Deenen, MJ; Mandigers, CM; Schellens, JH; Soesan, M; Terpstra, WE | 1 |
Itami, J; Ito, Y; Kondo, S; Mayahara, H; Morizane, C; Morota, M; Murakami, N; Okusaka, T; Sumi, M; Ueno, H | 1 |
Haruta, J | 1 |
Morimoto, M; Nakagawa, M; Tangoku, A | 1 |
Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Kogure, H; Koike, K; Maetani, I; Maguchi, H; Mukai, T; Nakai, Y; Okabe, Y; Sasahira, N; Sasaki, T; Toda, N; Yasuda, I | 1 |
Ayaki, M; Horie, S; Kashiwagi, R; Mitsuda, A; Tanaka, H | 1 |
Enomoto, K; Ito, M; Kurumatani, N; Matsumoto, S; Migita, K; Nakajima, Y; Saeki, K; Takayama, T; Tanaka, T; Wakatsuki, K | 1 |
Harada, N; Hayashi, T; Kaji, S; Koike, N; Ozaki, Y; Saida, S; Suzuki, M; Suzuki, S | 1 |
Asami, K; Atagi, S; Fujita, Y; Kawaguchi, T; Minomo, S; Okishio, K; Saitou, R; Takata, S; Tamura, A | 1 |
Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H | 1 |
Baba, H; Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fukutomi, A; Funakoshi, A; Furuse, J; Hatori, T; Ikeda, M; Ioka, T; Kitano, M; Mizumoto, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Shimamura, T; Sho, M; Sugimori, K; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K; Yanagimoto, H | 1 |
Endoh, T; Ikeda, K; Iwata, N; Minami, T; Sasano, H; Sugawara, N; Yoshida, Y | 1 |
Ilson, DH | 1 |
Benson, AB | 1 |
Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
de Gramont, A; Green, E; Haller, DG; McCleary, NJ; Meyerhardt, JA; O'Connell, M; Saltz, LB; Sargent, DJ; Twelves, CJ; Van Cutsem, E; Yothers, G | 1 |
Boku, N; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Mizusawa, J; Morizane, C; Okusaka, T; Takashima, A; Ueno, M | 1 |
Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K | 1 |
Akada, M; Egawa, S; Fujishima, F; Ishida, K; Katayose, Y; Motoi, F; Nakagawa, K; Oikawa, M; Okada, T; Ono, F; Ottomo, S; Shimamura, H; Takemura, S; Unno, M | 1 |
Chaulagain, CP; Rothschild, J; Saif, MW | 1 |
Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y | 1 |
Araki, K; Hachisuka, H; Iwamura, Y; Kushima, A; Nagano, K; Nakajima, T; Nakamoto, T; Nunomura, M; Takahashi, K; Takahashi, M; Wakata, M | 1 |
Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M | 1 |
Ajiki, T; Awane, M; Furuyama, H; Ikai, I; Ikezawa, K; Ioka, T; Kanai, M; Kou, T; Kume, M; Kuroda, N; Miyamoto, A; Nagano, H; Ochiai, T; Ogawa, M; Taira, K; Takeda, Y; Takemura, S; Terajima, H; Toyokawa, H; Tsukamoto, T; Yazumi, S | 1 |
Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY | 1 |
Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF | 1 |
Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K | 1 |
Qi, JL; Shi, SB; Tang, XY; Tian, J; Wang, M | 1 |
Akita, H; Doki, Y; Eguchi, H; Hama, N; Isohashi, F; Kawamoto, K; Kobayashi, S; Kudo, T; Mori, M; Nagano, H; Sakai, D; Satoh, T; Tomimaru, Y; Wada, H | 1 |
Furuse, J | 1 |
Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
Azemoto, R; Hara, T; Hirata, N; Ishihara, T; Mikata, R; Nakagawa, A; Nakaji, S; Nakamura, K; Nihei, T; Nishino, T; Ohshima, T; Ozawa, F; Shimura, K; Sudo, K; Tada, M; Tawada, K; Yamaguchi, T; Yokosuka, O | 1 |
Chen, G; Li, J; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X; Zhao, Z | 1 |
He, MM; Luo, HY; Qiu, MZ; Ren, C; Wang, F; Wang, FH; Wang, ZQ; Wu, WJ; Xu, RH; Zeng, ZL; Zhang, DS | 1 |
Cao, C; Chen, J; Chen, Y; Gong, Y; Gu, D; Shen, Y; Tang, C; Zhang, Q; Zhang, X | 1 |
Desaki, R; Higashi, M; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
Kaiho, T; Kobayashi, S; Nishimura, M; Okamoto, R; Okaniwa, A; Shimizu, W; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Ohira, M; Otani, H; Tanaka, H; Toyokawa, T | 1 |
Aoki, S; Egawa, S; Fukase, K; Hayashi, H; Katayose, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, T; Sakata, N; Unno, M; Yoshida, H | 1 |
Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tanizaki, K; Tomimaru, Y; Wada, H | 1 |
Doi, T; Fujishima, F; Kawaguchi, K; Kuroda, F; Motoi, F; Nozawa, Y; Takemura, S; Unno, M; Yokoyama, S | 1 |
Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Toyoki, Y; Wakiya, T | 1 |
Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K | 1 |
Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
Hiraoka, M; Itasaka, S; Kawaguchi, Y; Matsuo, Y; Mizowaki, T; Nakamura, A; Shibuya, K; Takaori, K; Uemoto, S; Yoshimura, M | 1 |
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
Harada, N; Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Matsuura, H; Morita, M; Okadome, K; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Uchiyama, H; Yamashita, Y; Yoshizumi, T | 1 |
Hasegawa, Y; Hatanaka, M; Iwata, H | 1 |
Iida, T; Nakabayashi, Y; Okui, N; Otsuka, M; Shiba, H; Yanaga, K | 1 |
Hara, K; Ishii, T; Kondo, H; Koyama, I; Morita, Y; Suzuki, A; Tashiro, J; Yamaguchi, S | 1 |
Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K | 1 |
Konno, F; Matsumoto, H; Mitsui, K; Namiki, K; Takahashi, T; Yoshida, R | 1 |
Ide, T; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, J; Noshiro, H | 1 |
Katsuno, A; Matsushita, A; Nakamura, Y; Sumiyoshi, H; Uchida, E; Yamahatsu, K | 1 |
Abe, T; Ensako, T; Hino, K; Nakamura, M; Nakashima, H; Yoshida, K | 1 |
Ikari, T; Ioka, T; Isayama, H; Ishii, H; Koike, K; Kwon, AH; Nakai, Y; Okusaka, T; Ozaka, M; Satoi, S; Shimokawa, T; Sho, M; Tanaka, M; Ueno, H; Yanagimoto, H | 1 |
Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
Castro-Rojas, C; Ortiz-Lópezj, R; Rojas-Martínez, A | 1 |
Ajiki, T; Eguchi, H; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kubo, S; Morita, S; Nagano, H; Sakai, D; Seo, S; Takemura, S; Taura, K; Terajima, H; Toyokawa, H; Tsuji, A; Yanagimoto, H | 1 |
Hanazaki, K; Iiyama, T; Iwata, J; Kobayashi, M; Kosaki, T; Kozuki, A; Morita, S; Okabayashi, T; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N | 1 |
Lin, RF; Luo, WH; Su, M; Wei, HP; Zhu, LC; Zou, CL | 1 |
Ahn, JB; Bello, M; Charoentum, C; Chen, LT; Cheng, AL; Ciardiello, F; de Lima Lopes, G; Ho, GF; Kim, TW; Köhne, CH; Kong, HL; Lam, KO; Li, J; Liu, TS; Ma, BB; Park, YS; Shaw, M; Sriuranpong, V; Sudoyo, AW; Teh, C; Vaid, AK; Wang, JY; Zhang, J; Zhang, SZ | 1 |
Aizawa, M; Nashimoto, A; Nomura, T; Sato, Y; Tsuchiya, Y | 1 |
Hara, Y; Minami, Y; Nakamura, T; Ueda, S | 1 |
Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y | 1 |
Hong, WD; Huang, QK; Liu, Y; Sun, XC; Wu, JM | 1 |
Du, W; Ke, QH; Lei, Y; Liang, G; Luo, F; Yang, JY; Zhou, SQ | 1 |
Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T | 1 |
Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ikuta, S; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Kubo, S; Marubashi, S; Miyamoto, A; Morita, S; Nagano, H; Sakai, D; Seo, S; Shiomi, H; Terajima, H; Yanagimoto, H | 1 |
Cai, J; Li, T; Wu, B; Xu, Y; Zhao, G | 1 |
Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Naruge, D; Okano, N; Takasu, A | 1 |
Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Koike, K; Maetani, I; Maguchi, H; Matsubara, S; Mukai, T; Nakai, Y; Okabe, Y; Sasaki, T; Toda, N; Yagioka, H; Yasuda, I | 1 |
Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY | 1 |
Magdy, T; Nies, AT; Schwab, M; Zanger, UM | 1 |
Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M | 1 |
Karasawa, H; Katagiri, M; Katayose, Y; Morikawa, T; Motoi, F; Naito, T; Sato, J; Unno, M; Yabuuchi, S | 1 |
Katayose, Y; Morikawa, T; Otsuka, H; Shirasaki, K; Unno, M | 1 |
Araki, H; Choda, Y; Harano, M; Idani, H; Kanazawa, T; Kato, T; Matsukawa, H; Mimura, N; Miyake, S; Miyoshi, H; Ninomiya, M; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Taguchi, K; Takahashi, K; Tokumoto, N; Toshima, T; Yamaguchi, K; Yoshida, K | 1 |
Deguchi, S; Goto, W; Inoue, T; Ishikawa, A; Kanazawa, A; Kotsuka, M; Kurihara, S; Mori, Y; Nakajima, T; Nishiguchi, Y; Ohira, G; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tashima, T; Tsukamoto, T; Yamamoto, A; Yamashita, Y; Yoshii, M | 1 |
Ishii, J; Kaneko, H; Katagiri, T; Koda, T; Kubota, Y; Maeda, T; Otsuka, Y; Shibuya, K; Tamura, A; Tsuchiya, M | 1 |
Matsui, K; Moriyama, M; Nagata, T; Osawa, S; Sawada, S; Shibuya, K; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
Aisu, Y; Andoh, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Nakayama, A; Ohta, T; Shoji, M; Tajima, H; Takamura, H | 1 |
Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N | 1 |
Hirai, K; Igarashi, T; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yamazaki, H; Yokoo, H; Yoshinari, D | 1 |
Du, Z; He, X; Li, Q; Tang, R; Wen, F; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
Jiang, Z; Li, Y; Liu, G; Sun, J; Zhang, L | 1 |
Chen, D; Hu, J; Huang, W; Li, N; Wan, Z; Wang, L; Xue, P; Yang, H; Zhu, L | 1 |
Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H | 1 |
Katoh, M; Kubota, K; Shimizu, T; Shimoda, M | 1 |
Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
Motoi, F; Unno, M | 1 |
Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D | 1 |
Araki, M; Endo, S; Hamano, Y; Hasegawa, N; Hyodo, I; Imanishi, M; Ishida, H; Ito, Y; Kobayashi, M; Moriwaki, T; Sato, D; Shimoyamada, M; Sugaya, A; Yoshida, S | 1 |
Baba, H; Egawa, N; Fukutomi, A; Funakoshi, A; Hamada, C; Hamamoto, Y; Hosotani, R; Hyodo, I; Ichikawa, Y; Ikeda, M; Isayama, H; Ishii, H; Matsumoto, S; Nagase, M; Nakamori, S; Ohkawa, S; Okusaka, T; Omuro, Y; Sho, M; Takahashi, S; Tsuchiya, Y; Tsuda, M; Unno, M; Wakabayashi, G; Watanabe, G; Yamada, N; Yamaguchi, K; Yanagimoto, H | 1 |
Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
Chen, MW; Huang, HQ; Huang, JJ; Jiang, DK; Lu, DC; Wu, FL; Yang, X; Ying, YP; Zeng, HY; Zhou, AM; Zhou, J | 1 |
Fujino, Y; Goto, H; Hasegawa, H; Kakinoki, K; Katsura, M; Ohara, T; Oshikiri, T; Oyama, M; Sendo, H; Sugimoto, T; Sugiyama, H; Tominaga, M; Ueda, Y; Yamashita, H; Yasuda, T | 1 |
Korytov, OV; Korytova, LI; Krasnikoval, VG; Meshechkin, AV; Sandalevskaya, AG | 1 |
Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Miyazawa, S; Okuwaki, K; Takezawa, M; Watanabe, A; Yamauchi, H | 1 |
Furukawa, K; Sakamoto, T; Shiba, H; Tsutsumi, J; Uwagawa, T; Yanaga, K | 1 |
Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K | 1 |
Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
Fujikawa, K; Fujino, Y; Goji, T; Ikushima, H; Kagemoto, K; Kimura, M; Kimura, T; Kitamura, S; Matsumoto, S; Mitsui, Y; Miyamoto, H; Miyamoto, Y; Muguruma, N; Okada, Y; Okahisa, T; Okamoto, K; Okazaki, J; Sagawa, T; Sato, Y; Sogabe, M; Sueuchi, T; Takaoka, T; Takaoka, Y; Takayama, T; Takehara, M; Tanaka, K | 1 |
Skoropad, VY | 1 |
Bi, Z; Chen, C; Chen, R; Fan, X; Li, D; Li, Z; Liu, Y; Zhou, Y | 1 |
He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H | 1 |
Cao, C; Chen, J; Kuang, M; Tang, C; Xu, W; Zhang, X | 1 |
Ashida, R; Ioka, T; Katayama, K; Sakon, M; Takahashi, H; Teshima, T | 1 |
Baba, H; Boku, N; Fukutomi, A; Fukuzawa, K; Furukawa, M; Furuse, J; Hyodo, I; Iguchi, H; Ikeda, M; Ioka, T; Isayama, H; Komatsu, Y; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Shimada, K; Sugimori, K; Takeuchi, M; Ueno, M | 1 |
Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H | 1 |
Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
Natsui, M; Seino, S; Tsuchiya, A | 1 |
Egawa, S; Hara, K; Hijioka, S; Imaoka, H; Kou, T; Mizuno, N; Shimizu, Y; Tanaka, M; Yamao, K; Yazumi, S | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
Asano, T; Kanomata, H; Matsuoka, Y; Miyamoto, Y; Murayama, M; Seyama, Y; Takahashi, M; Tani, K; Tanizawa, T; Umekita, N; Warabi, M | 1 |
Abe, T; Aoki, S; Hayashi, H; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, R; Okada, Y; Oyauchi, M; Sakata, N; Unno, M; Yoshida, H | 1 |
Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 2 |
Fukada, T; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K | 1 |
Hasegawa, J; Kobayashi, T; Naito, T; Sakata, J; Shimada, T; Shimakage, N; Tani, T; Usui, K; Wakai, T; Yamamoto, J | 1 |
Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Maeda, S; Miyazaki, M; Ohtsuka, M; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
Hashimoto, M; Hayashi, H; Ikeda, Y; Ishii, T; Katayama, T; Kawasaki, Y; Ohtsuru, M; Okubo, Y; Senba, H; Shinozaki, K; Tono, T; Yasuda, S | 1 |
Fujiwara, H; Hatakeyama, T; Ichikawa, D; Ikoma, H; Imamura, T; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
Hirose, Y; Kameyama, H; Kobayashi, T; Kosugi, S; Minagawa, M; Miura, K; Morimoto, Y; Nagahashi, M; Sakata, J; Sato, R; Soma, D; Takano, K; Takizawa, K; Wakai, T; Yuza, K | 1 |
Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Matsumoto, T; Takebe, A; Tanaka, M; Terai, S; Toyama, H | 1 |
Anazawa, T; Doi, R; Ito, T; Kawaguchi, Y; Masui, T; Nakano, K; Sato, A; Takaori, K; Uemoto, S | 1 |
Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D | 1 |
Chang, T; Egawa, N; Honda, G; Kamisawa, T; Karasawa, K; Kobayashi, S; Kurata, M; Okuda, Y; Omuro, Y; Sakamoto, K; Tsuruta, K | 1 |
Fukuda, H; Furuse, J; Ishii, H; Katayama, H; Mizusawa, J; Morizane, C; Okusaka, T | 1 |
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z | 1 |
Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ | 1 |
Asai, K; Asayama, Y; Honda, H; Matsumoto, K; Nakamura, K; Nishie, A; Ohga, S; Sasaki, T; Shinoto, M; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
Katata, Y; Okawaki, M; Sawaki, A; Yamaguchi, Y; Yamamura, M | 1 |
Akahoshi, K; Ban, D; Kirimura, S; Kudo, A; Matsumura, S; Minoru, T; Mitsunori, Y; Oba, A; Ochiai, T; Tanaka, S | 1 |
Hirooka, S; Inoue, K; Kon, M; Matsui, Y; Michiura, T; Miyasaka, C; Ohe, C; Ryota, H; Satoi, S; Tanigawa, N; Uemura, Y; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
Ko, AH | 1 |
Date, K; Fujimoto, T; Kimura, H; Matsunaga, T; Miyasaka, Y; Mochidome, N; Mori, Y; Nakamura, M; Oda, Y; Ohtsuka, T | 1 |
Goda, Y; Hara, H; Irie, K; Kobayashi, S; Morimoto, M; Moriya, S; Ohkawa, S; Okusaka, T; Tanaka, M; Tezuka, S; Ueno, M | 1 |
Fukuda, S; Kuga, Y; Moriya, T; Nishida, T | 1 |
Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
Furukawa, D; Hirabayashi, K; Izumi, H; Mashiko, T; Nakagohri, T; Ozawa, S; Sadahiro, S; Tomioku, M; Yasuda, S; Yazawa, N | 1 |
Azakami, T; Eguchi, N; Hayashi, H; Matsumoto, K; Shimamoto, F; Sumida, T; Sumii, M; Sumimoto, K; Tamura, T; Uraoka, N | 1 |
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomihara, H; Wada, H; Yamada, D | 1 |
Hu, Z; Ju, B; Lu, S; Wang, W; Xie, H; Yang, Q; Zhang, Y; Zhao, X; Zheng, S; Zhou, D; Zhou, L; Zhou, X | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
Arigami, T; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Mori, S; Natsugoe, S; Sakoda, M; Shinchi, H; Uchikado, Y; Ueno, S; Uenosono, Y | 1 |
Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T | 1 |
Akiyama, D; Isayama, H; Ishigaki, K; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Uchino, R; Yagioka, H | 1 |
Asaoka, T; Doki, Y; Eguchi, H; Goto, K; Kawamoto, K; Mori, M; Noda, T; Ueno, G; Wada, H; Yamada, D | 1 |
Abe, T; Fukase, K; Hayashi, H; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Otsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
Fukuda, S; Harada, T; Hiraki, S; Kanesada, K; Tada, K | 1 |
Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E | 1 |
Ito, F; Kaneta, A; Miura, J; Otani, S; Saito, T; Tsuchiya, T | 1 |
Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, K; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Uemura, M; Yamamoto, K | 1 |
Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M | 1 |
Kaito, A; Kinoshita, T; Nishida, T; Shibasaki, H; Shitara, K | 1 |
Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fujii, H; Funakoshi, A; Furuse, J; Hamamoto, Y; Hatori, T; Ioka, T; Ito, T; Maguchi, H; Matsumoto, S; Miyakawa, H; Mizumoto, K; Nakamori, S; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Satoh, T; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K | 1 |
Arigami, T; Kijima, Y; Kurahara, H; Maemura, K; Mataki, Y; Matsushita, D; Natsugoe, S; Okubo, K; Sakoda, M; Uenosono, Y; Yanagita, S | 1 |
Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Okada, K; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A | 1 |
Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T | 1 |
Endo, I; Kubota, K; Kumamoto, T; Matsuyama, R; Mori, R; Sakamaki, K; Taniguchi, K; Yabushita, Y | 1 |
Hara, R; Kita, E; Nakamura, K; Sudo, K; Tsujimoto, A; Yamaguchi, T | 1 |
Asada, H; Miyagawa, F; Sho, M; Sugano, Y | 1 |
Ge, L; Qie, S; Wang, Z; Yan, Q; Yang, L; Zhong, S | 1 |
Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N | 1 |
Itai, R; Yamashita, Y; Yokode, M; Zen, Y | 1 |
Kondo, N; Murakami, Y; Nakagawa, N; Okano, K; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
Fujii, Y; Fujita, H; Fujita, J; Kinami, S; Kosaka, T; Miura, S; Motoo, Y; Nakano, Y; Ohnishi, T; Omote, K; Tomita, Y; Ueda, N | 1 |
Hori, T; Kaizaki, R; Kanazawa, A; Kodai, S; Komatsu, R; Takahama, M; Takatsuka, S; Tsukamoto, T | 1 |
Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J | 1 |
Chae, H; Kim, HI; Kim, IH; Kim, MC; Kwon, IK; Lee, CM; Lee, HH; Lee, SI; Min, JS; Park, SS | 1 |
Boku, N; Fukutomi, A; Hagiwara, Y; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
Ajioka, Y; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Nishikura, K; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A; Watanabe, G | 1 |
Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N; Yamauchi, Y | 1 |
Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K | 1 |
An, JY; Kim, S; Kim, SM; Lee, J; Sohn, TS | 1 |
Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R | 1 |
Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
Izumiya, Y; Kawakami, S; Kimura, Y; Kin, S; Komiyama, S; Nakashima, S | 1 |
Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y | 1 |
Cai, Z; Chen, Z; Shen, C; Wang, J; Yin, X; Yin, Y; Zhang, B; Zhou, Y | 1 |
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Yamada, D | 1 |
Huang, KW; Kim, MD; Li, SP; Liang, PC; Pua, U; Qiu, YD; Song, TQ; Yang, PC | 1 |
Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y | 1 |
Nishibuchi, I; Wadasaki, K | 1 |
Saito, K; Sato, A; Takahata, T; Yu, C | 1 |
Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
Babazono, A; Fujita, T; Harano, Y; Jiang, P | 1 |
Gou, H; Yi, C; Zhao, Y; Zhu, H | 1 |
Ajiki, T; Gotoh, K; Hatano, E; Hirose, T; Ikai, I; Ioka, T; Kamei, K; Kobayashi, S; Morita, S; Nagano, H; Sakai, D; Satake, H; Seo, S; Terajima, H; Tohyama, T; Tomokuni, A; Uchida, Y | 1 |
Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N | 1 |
Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S | 1 |
Furuse, J; Honda, G; Kosuge, T; Matsumoto, I; Matsuyama, Y; Motoi, F; Satoi, S; Sho, M; Ueno, H; Unno, M; Wada, K; Yamaue, H | 1 |
Bian, Y; Cao, K; Gao, S; Guo, S; Jiang, H; Jin, G; Shi, X; Wang, K; Zhang, H; Zhu, X | 1 |
Cheng, SH; Cheng, YJ; Jin, ZY; Xue, HD | 1 |
Fukumitsu, K; Ishii, T; Kaido, T; Morino, K; Nishino, H; Okajima, H; Seo, S; Taura, K; Uemoto, S; Yamanaka, K; Yoh, T | 1 |
Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H | 1 |
Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ | 1 |
Endo, I; Hata, M; Homma, Y; Ito, E; Kaizu, H; Koike, I; Kumamoto, T; Matsuyama, R; Mukai, Y; Sato, M; Sawada, Y; Sugiura, M; Takano, S; Yabushita, Y | 1 |
Chang, CF; Chang, PH; Chen, JS; Chen, YY; Chou, WC; Hsueh, SW; Huang, PW; Hung, CY; Hung, YS; Lu, CH; Yeh, KY | 1 |
Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y | 1 |
Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S | 1 |
Fushida, S; Gabata, R; Harmon, JW; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Shimbashi, H; Tajima, H; Takamura, H | 1 |
Gou, H; Huang, J; Li, Q; Liao, W; Wang, X; Wen, F; Wu, Q; Zhang, P; Zhou, J; Zhou, K; Zhu, G | 1 |
Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takagi, A; Takeuchi, O; Watanabe, K | 1 |
Huang, KW; Kim, MD; Li, SP; Li, XY; Liang, PC; Pua, U; Yang, PC | 1 |
Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
Akhoundova Sanoyan, D; Lamarca, A; McNamara, MG; Valle, JW | 1 |
Iede, K; Ikenaga, M; Kato, R; Matsuyama, J; Nakashima, S; Ohta, K; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 1 |
Furuse, J; Ikeda, M; Imaoka, H; Inoue, H; Kawamoto, Y; Kobayashi, S; Maehara, K; Morizane, C; Nagano, H; Okamura, K; Ozaka, M; Sakaguchi, C; Shioji, K; Shirakawa, H; Suzuki, R; Terashima, T; Tsuji, K; Ueno, M; Umemoto, K | 1 |
Ban, D; Esaki, M; Furuse, J; Ioka, T; Ishii, H; Nara, S; Okusaka, T; Shimada, K; Takamoto, T | 1 |
Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
Arai, T; Fukumura, Y; Hirabayashi, K; Kawanishi, A; Kojima, M; Matsuda, Y; Mino-Kenudson, M; Nakano-Narusawa, Y; Ohkubo, S; Sahara, Y; Takahashi, S; Yamaguchi, H | 1 |
Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
Hua, YQ; Meng, ZQ; Ning, ZY; Shen, YH; Sheng, J; Wang, P; Xu, LT; Yan, X; Zhu, ZF; Zhuang, LP | 1 |
Bai, LY; Chen, CY; Chen, LT; Chiang, NJ; Chiu, CF; Liang, SH; Su, YY; Wang, HC | 1 |
Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
Furukawa, T; Higuchi, R; Izumo, W; Matsunaga, Y; Shiihara, M; Uemura, S; Yamamoto, M; Yazawa, T | 1 |
Fukutomi, A; Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Kajiwara, T; Katanuma, A; Kobayashi, S; Komatsu, Y; Makino, K; Mizuno, N; Moriwaki, T; Morizane, C; Muto, M; Nakai, Y; Negoro, Y; Nemoto, N; Ozaka, M; Sakai, D; Shimizu, S; Tsuda, M; Tsuji, A; Ueno, M | 1 |
Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
Hashimoto, D; Hirooka, S; Inoue, K; Ishida, M; Ryota, H; Sakaguchi, T; Satoi, S; Sekimoto, M; Yamaki, S; Yamamoto, T | 1 |
Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H | 1 |
Chiba, Y; Fukuoka, M; Higashiyama, M; Iked, N; Katakami, N; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Negoro, S; Nomori, H; Oda, M; Ohta, M; Saka, H; Sawa, T; Semba, H; Seto, T; Shimokawa, M; Tada, H; Yamaguchi, M; Yamashita, M; Yokoi, K | 1 |
Fukushima, K; Hayashi, H; Hosoda, K; Kobayashi, R; Kubota, K; Motoyama, H; Notake, T; Shimizu, A; Soejima, Y; Sugenoya, S; Yasukawa, K | 1 |
Dai, GH; Deng, GC; Han, QL; Lv, Y; Pan, YT; Qu, TT; Sun, DC; Yan, H | 1 |
Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okamura, K; Okano, N; Okusaka, T; Oono, T; Sekimoto, M; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamada, I; Yamaguchi, H; Yamashita, T | 1 |
Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H | 1 |
Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M | 1 |
93 review(s) available for tegafur and deoxycytidine
Article | Year |
---|---|
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorodeoxyuridylate; Fluorouracil; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Tegafur | 1993 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasms; Polysaccharides, Bacterial; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidylate Synthase; Uracil | 1995 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
Oral 5-FU analogues in the treatment of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Humans; Tegafur; Uracil | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
The oral fluorouracil prodrugs.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1998 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxidoreductases; Pyridines; Tegafur; Uracil | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasms; Tegafur; Time Factors; Uracil | 1998 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
The oral fluoropyrimidines in cancer chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Tegafur | 1999 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; Guanine; Humans; Pemetrexed; Platinum Compounds; Pyridines; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Oral fluoropyrimidines: a closer look at their toxicities.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Tegafur; Uracil | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Oxidoreductases; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidine Phosphorylase; Thymidylate Synthase; Uracil | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
Oral therapy for colorectal cancer: how to choose.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availability; Capecitabine; Colorectal Neoplasms; Decision Making; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Tegafur; Uracil | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2000 |
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Oxidoreductases; Prodrugs; Pyrimidines; Tegafur; Uracil | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Neoplasms; Oxidoreductases; Prodrugs; Tegafur; Uracil | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Outpatients; Tegafur; Uracil | 2001 |
Answering patients' needs: oral alternatives to intravenous therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Patient Satisfaction; Quality of Life; Tegafur; Uracil | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cryosurgery; Deoxycytidine; Drug Combinations; Ethanol; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Injections, Intralesional; Interferons; Liver Cirrhosis; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Tamoxifen; Tegafur; Uracil | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Pyrimidines; Tegafur; Uracil | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Patient Compliance; Prodrugs; Pyridines; Tegafur; Treatment Outcome | 2001 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 2003 |
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Tegafur; Uracil | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Oxonic Acid; Prognosis; Pyridines; Tegafur; Thymidylate Synthase; Uracil | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Metastasis; Tegafur; United Kingdom; Uracil | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyrimidinones; Tegafur; Uracil | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Neoplasms; Oxonic Acid; Prodrugs; RNA, Messenger; Tegafur; Thymidylate Synthase | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
[Recent important insights into treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Intraoperative Care; Lymph Node Excision; Lymphatic Metastasis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pyridines; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Treatment Outcome | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
[Chemotherapy for biliary tract cancers: general remarks].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Cytarabine; Deoxycytidine; Doxorubicin; Drug Therapy; Gemcitabine; Humans; Tegafur; Treatment Outcome | 2006 |
[5 -fluoropyrimidines for treatment of biliary tract cancers].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Pyridines; Pyrimidines; Tegafur; Uracil | 2006 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
[Non-surgical treatment for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Tegafur | 2006 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; State Medicine; Tegafur; Treatment Outcome; United Kingdom; Uracil | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
[Diagnosis of and therapy for pancreatic neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Diabetes Complications; Drug Combinations; Early Diagnosis; Gemcitabine; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tegafur | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Death; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil; Vascular Endothelial Growth Factor A | 2007 |
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Immunologic Factors; Liver Neoplasms; Tegafur | 2008 |
Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Japan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
[A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Japan; Methotrexate; Oxonic Acid; Tegafur; Uracil | 2010 |
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2011 |
Applications of oral fluoropyrimidines in colon cancer: their role and new directions.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxaloacetates; Oxonic Acid; Tegafur; Uracil | 2003 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Humans; Neoplasm Staging; Odds Ratio; Oxonic Acid; Publication Bias; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2013 |
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Odds Ratio; Oxonic Acid; Proportional Hazards Models; Publication Bias; Tegafur; Treatment Outcome | 2014 |
[Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Tegafur; Treatment Outcome | 2013 |
[A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur; Treatment Outcome | 2014 |
[Pharmacogenomics of the first-line treatment for gastric cancer: advances in the identification of genomic biomarkers for clinical response to chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers; Biotransformation; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Enzymes; Ethnicity; Fluorouracil; Gastrectomy; Humans; Mexico; Molecular Targeted Therapy; Organoplatinum Compounds; Oxonic Acid; Patient Selection; Pharmacogenetics; Precision Medicine; Prodrugs; Stomach Neoplasms; Tegafur | 2014 |
The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur | 2015 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Camptothecin; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Neoplasms; Organoplatinum Compounds; Tegafur | 2015 |
[A case of pancreatic cancer with distant metastasis successfully resected after neoadjuvant chemotherapy with a combination of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Pancreatic Neoplasms; Pleural Neoplasms; Stomach Neoplasms; Tegafur | 2014 |
Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Survival Rate; Tegafur; Treatment Outcome | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Topics: Capecitabine; China; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Oxonic Acid; Severity of Illness Index; Stomach Neoplasms; Tegafur | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Odds Ratio; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Report; Tegafur; Treatment Outcome | 2015 |
Autopsy of anaplastic carcinoma of the pancreas producing granulocyte colony-stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Carcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2016 |
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2017 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
[A Distal Bile Duct Carcinoma Patient Who Underwent Surgical Resection for Liver Metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2018 |
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Lymph Node Excision; Network Meta-Analysis; Oxaloacetates; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur | 2018 |
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Multicenter Studies as Topic; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2020 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
122 trial(s) available for tegafur and deoxycytidine
Article | Year |
---|---|
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA, Neoplasm; Drug Administration Routes; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Ribonucleotide Reductases; Tegafur; Treatment Outcome; Uracil | 1999 |
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fever; Gemcitabine; Hematologic Diseases; Humans; Kidney; Liver; Lung Neoplasms; Nausea; Neoplasm Staging; Tegafur; Uracil | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Combinations; Fluorouracil; Humans; Leucovorin; Nausea; Survival Rate; Tegafur; Time Factors; Uracil | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Statistics, Nonparametric; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2002 |
Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2002 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Tegafur; Uracil | 2004 |
Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Tegafur; Treatment Outcome | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constipation; Cyclophosphamide; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome; Uracil | 2005 |
UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Pyridines; Tegafur; Time Factors; Treatment Outcome | 2005 |
Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Uracil | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prodrugs; Tegafur; Uracil | 2006 |
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Aged; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur; Time Factors | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2006 |
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2007 |
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Survival Analysis; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Tegafur; Uracil | 2008 |
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Injections, Intravenous; Japan; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Survival Rate; Tegafur | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
[Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Hyperglycemia; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2009 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Safety; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2010 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Tegafur | 2011 |
Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Oxonic Acid; Patient Selection; Sample Size; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gastroesophageal Reflux; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Tegafur | 2010 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2011 |
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2011 |
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
[Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2012 |
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2012 |
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2012 |
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2012 |
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Thrombocytopenia; Treatment Outcome | 2012 |
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2012 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2013 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Republic of Korea; Tegafur | 2012 |
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Tegafur | 2013 |
Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Tegafur; Uracil; Vinblastine; Vinorelbine | 2013 |
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Taiwan; Tegafur; Treatment Outcome | 2013 |
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Tegafur | 2013 |
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HLA Antigens; Humans; Immunoglobulins; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peptide Fragments; Precision Medicine; Prognosis; Survival Rate; Tegafur; Vaccination; Young Adult | 2013 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tegafur | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
S-1 plus CIK as second-line treatment for advanced pancreatic cancer.
Topics: Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2013 |
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Treatment Outcome | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Risk; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatectomy; Humans; Male; Neutropenia; Postoperative Care; Pyridines; Tegafur; Treatment Outcome | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Stomatitis; Survival Analysis; Tegafur; Treatment Outcome; Venous Thrombosis | 2014 |
S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prodrugs; Survival Analysis; Tegafur | 2015 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2014 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2015 |
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Tegafur | 2015 |
Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Survival Rate; Tegafur; Young Adult | 2015 |
Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2015 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyrimidines; Tegafur | 2015 |
Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer.
Topics: Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2015 |
[Immediate results of combined therapy for local recurrences of rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Radiation Injuries; Rectal Neoplasms; Severity of Illness Index; Tegafur; Treatment Outcome | 2015 |
Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2015 |
A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2016 |
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2015 |
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Oxonic Acid; Patient Selection; Tegafur; Treatment Outcome | 2016 |
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Klatskin Tumor; Male; Middle Aged; Oxonic Acid; Tegafur | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Tegafur | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur | 2016 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome; Vomiting | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2017 |
Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2017 |
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Rate; Tegafur | 2018 |
WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tegafur; WT1 Proteins | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Postoperative Care; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2019 |
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2019 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Republic of Korea; Tegafur; Time Factors | 2019 |
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2019 |
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Survival Rate; Tegafur; Young Adult | 2019 |
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2019 |
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Nausea; Oxonic Acid; Tegafur; Vomiting | 2019 |
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tegafur | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Hydroxamic Acids; Japan; Male; Middle Aged; Oxonic Acid; Placebos; Platinum Compounds; Progression-Free Survival; Sulfonamides; Tegafur; Young Adult | 2021 |
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Tegafur; Uracil | 2021 |
288 other study(ies) available for tegafur and deoxycytidine
Article | Year |
---|---|
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Intestinal permeability in patients with chemotherapy-induced stomatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Intestinal Absorption; Intestinal Mucosa; Lactulose; Leucovorin; Male; Mannitol; Middle Aged; Paclitaxel; Permeability; Stomatitis; Tegafur; Treatment Outcome; Xylose | 2001 |
Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Tegafur; Uracil | 2001 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2002 |
Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Approval; European Union; Humans; Leucovorin; Neoplasm Staging; Tegafur; Uracil | 2002 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
[Effective treatment with the additional administration of UFT for refractory malignant pleural effusion secondary to adenocarcinoma of the lung after the treatment regimen of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Tegafur; Uracil; Vinblastine; Vinorelbine | 2003 |
[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cholestasis; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Heart Failure; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Stents; Survivors; Tegafur; Uracil | 2004 |
[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms; Quality of Life; Tegafur; Uracil | 2004 |
[A case of successful treatment with combined 5-fluorouracil, adriamycin, cisplatin (FAP) therapy followed by Gemcitabine, UFT therapy and intra-arterial FAP therapy for unresectable advanced gallbladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Tegafur; Uracil | 2004 |
Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.
Topics: Adult; Aged; Contrast Media; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Pancreatic Neoplasms; Polysaccharides; Prognosis; Pyridines; Survival Analysis; Survival Rate; Tegafur; Ultrasonography | 2005 |
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Tegafur; Thymidine Phosphorylase; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2005 |
[Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Stents; Tegafur | 2005 |
[A case of advanced pancreatic cancer treated with chemoradiation].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Risk Assessment; Tegafur; Uracil | 2006 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA, Messenger; Tegafur; Uracil; Xenograft Model Antitumor Assays | 2006 |
[A patient with pancreatic cancer and multiple liver metastases after total pancreatectomy who showed a partial response to combination chemotherapy with gemcitabine and UFT].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
[A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survivors; Tegafur; Uracil | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Tegafur; United Kingdom; Uracil | 2007 |
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2007 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Skin Neoplasms; Tegafur; Toremifene | 2007 |
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Edema; Capecitabine; Dementia, Vascular; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Energy Metabolism; Female; Fluorouracil; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Injections, Spinal; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasms; Nerve Fibers, Myelinated; Neurologic Examination; Registries; Remission, Spontaneous; Stroke; Tegafur | 2008 |
[A case of unresectable advanced pancreatic cancer with peritoneal dissemination responding to continuous dose S-1 monotherapy after chemo-radiation therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Cavity; Peritonitis; Quality of Life; Tegafur | 2007 |
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur | 2007 |
A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
Oral treatment for gastric cancer: new choices, better choices?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Japan; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2008 |
Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Tegafur | 2008 |
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Tegafur; Thrombospondin 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
[A long-term survival case of unresectable malignant pancreatic endocrine tumor successfully treated with systemic chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiography; Tegafur | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
[A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tegafur; Treatment Outcome | 2009 |
Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Evidence-Based Medicine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Tegafur; Uracil | 2008 |
[A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2009 |
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
[Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiosurgery; Remission Induction; Survival Rate; Tegafur | 2008 |
S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2009 |
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Palliative Care; Pyrimidinones; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2008 |
[S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Prohibitins; Tegafur; Tomography, X-Ray Computed | 2008 |
[Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2008 |
[Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
[Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Positron-Emission Tomography; Tegafur | 2009 |
[A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
[Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Uracil | 2009 |
[A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine].
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Duodenal Neoplasms; Gemcitabine; Humans; Jaundice, Obstructive; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
The usefulness of perfusion-weighted magnetic resonance imaging in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sex Factors; Tegafur | 2009 |
Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constriction, Pathologic; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Portal; Liver Diseases; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Stents; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
[Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Uracil | 2009 |
[A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Recurrence; Tegafur; Tomography, X-Ray Computed | 2009 |
A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Drug Therapy; Female; Gemcitabine; Humans; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Tegafur | 2009 |
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Hepatectomy; Humans; Immunosuppressive Agents; Japan; Male; Oxonic Acid; Pancreaticoduodenectomy; Postoperative Care; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2009 |
[A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2009 |
[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
[A case report-neoadjuvant chemoradiotherapy with combination of S-1 and gemcitabine in a patient with locally advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy; Tegafur | 2009 |
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2010 |
[Current status of adjuvant chemotherapy for resected lung cancer at our institute--focus on clinical trial enrollment].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Small Cell Lung Carcinoma; Tegafur; Uracil; Vinblastine; Vinorelbine | 2010 |
[Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2010 |
Impact of S-1 on the survival of patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2010 |
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Palliative Care; Prognosis; Survival Rate; Tegafur; Tumor Burden; Young Adult | 2011 |
[A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Remission Induction; Tegafur | 2010 |
[A case of abdominal wall metastasis from pancreatic cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cimetidine; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Hypertension; Interferon-alpha; Life Style; Neoplasms; Oxonic Acid; Renin-Angiotensin System; Tegafur; Tetrazoles | 2010 |
PharmGKB summary: fluoropyrimidine pathways.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Databases, Factual; Deoxycytidine; Fluorouracil; Genome, Human; Humans; Pharmacogenetics; Tegafur | 2011 |
[A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
[S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Ultrasonography | 2010 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2010 |
[A long-term survivor treated with S-1 and gemcitabine for recurrence following an operation for advanced gall bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bile; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Tegafur; Treatment Failure | 2011 |
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Prodrugs; Rectal Neoplasms; Tegafur | 2010 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2010 |
[A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
Topics: Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Tegafur | 2010 |
[A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2010 |
[Evaluation of systemic chemotherapy for unresectable gallbladder carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2010 |
[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Tegafur; Treatment Outcome | 2010 |
Curative surgical treatment after preoperative chemotherapy for primarily inoperable locally advanced pancreatic carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Two cases of curatively resected intrahepatic cholangiocellular carcinomas through effective response to neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography Scanners, X-Ray Computed | 2011 |
[A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Acinar Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Fingers; Gangrene; Gemcitabine; Humans; Ischemia; Male; Necrosis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Raynaud Disease; Scleroderma, Systemic; Tegafur; Toes | 2011 |
[A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Salvage Therapy; Tegafur | 2011 |
[Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Proportional Hazards Models; Tegafur | 2012 |
Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; France; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies; Tegafur; Vitamin B Complex | 2012 |
[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2011 |
Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Statistics, Nonparametric; Tegafur | 2012 |
Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
[A case of locally advanced pancreas cancer effectively treated by multidisciplinary strategy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[Curative resection of gallbladder cancer with simultaneous liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
[A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
[A case of curatively resected locally advanced cancer of the pancreatic body treated by distal pancreatectomy with en bloc celiac axis resection after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Tegafur | 2012 |
High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Telomerase; Young Adult | 2012 |
[A case of pancreatic cancer with celiac trunk and common hepatic artery invasion successfully resected after gemcitabine+S-1therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; S Phase; Tegafur | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
Poorly differentiated neuroendocrine carcinoma of the pancreas responsive to combination therapy with gemcitabine and S-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Prognostic significance of aquaporins in human biliary tract carcinoma.
Topics: Aged; Aged, 80 and over; Aquaporin 1; Aquaporin 4; Aquaporin 5; Aquaporins; Bile Duct Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Tegafur | 2012 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2012 |
A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2012 |
[A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Stents; Tegafur | 2012 |
Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Comorbidity; Deoxycytidine; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2013 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2012 |
[A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Male; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Prognosis; Tegafur | 2012 |
[Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur | 2012 |
Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Time Factors | 2013 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Genetic Testing; Genotype; Humans; Male; Middle Aged; Neoplasms; Risk Assessment; Tegafur | 2012 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2012 |
[Questions on "gemcitabine plus S-1 combination therapy (G-S therapy) for pancreatic cancer with accentuated hepatic metastasis" (by Matsumoto, T. et al) published on Japanese Journal of Gastro-enterology Vol. 108, N0. 12].
Topics: Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[Oral chemotherapy for advanced breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Molecular Targeted Therapy; Oxonic Acid; Tegafur | 2012 |
[A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur | 2013 |
The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Lymphocyte Count; Male; Middle Aged; Nutritional Status; Oxonic Acid; Predictive Value of Tests; Retrospective Studies; Serum Albumin; Stomach Neoplasms; Tegafur; Time Factors; Uracil; Young Adult | 2013 |
Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Etoposide; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Methotrexate; Organoplatinum Compounds; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colectomy; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2013 |
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Peripheral Nerves; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2013 |
Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaloacetates; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2013 |
Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2014 |
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genotype; Humans; Incidental Findings; Male; Risk Assessment; Sex Factors; Tegafur | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2013 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur; Tumor Microenvironment | 2014 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Middle Aged; Models, Statistical; Oxaloacetates; Oxonic Acid; Probability; Quality-Adjusted Life Years; Stomach Neoplasms; Tegafur | 2013 |
[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
[A case of effective multidisciplinary treatment for advanced gallbladder carcinoma with distant lymph node metastases].
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Quality of Life; Tegafur | 2013 |
[A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2013 |
[A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A case of curatively resected locally advanced pancreatic cancer with combined resection of the portal vein and common hepatic artery after neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2014 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pain Measurement; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Tegafur | 2014 |
Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2013 |
[A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Time Factors | 2014 |
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2014 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Uracil; Young Adult | 2014 |
[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Rectal Neoplasms; Tegafur | 2014 |
[Radical resection of a locally advanced pancreatic tail adenosquamous carcinoma treated with S-1 and gemcitabine as neoadjuvant chemotherapy - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis.
Topics: Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Care; Preoperative Care; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Oxonic Acid; Panitumumab; Practice Guidelines as Topic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
[Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fatal Outcome; Fluorouracil; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Severity of Illness Index; Survival Rate; Tegafur | 2015 |
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiosurgery; Radiotherapy, Conformal; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2014 |
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Tegafur | 2014 |
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Models, Economic; Oxaloacetates; Oxonic Acid; Quality-Adjusted Life Years; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Inflammation; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2015 |
[A case of advanced gallbladder cancer with mediastinum lymph node metastasis successfully treated with multimodality therapy].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Mediastinal Neoplasms; Tegafur; Uracil | 2014 |
[A long term survival case of hilar cholangiocarcinoma with multiple metastases treated with chemotherapy and operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Catheter Ablation; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Oxonic Acid; Tegafur | 2014 |
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Lymph Node Excision; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2014 |
[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2014 |
[A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2014 |
[A case of resection for a huge pancreatic acinar cell carcinoma with tumor thrombus in the portal vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Prognosis; Tegafur; Thrombosis | 2014 |
[A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Laser Therapy; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Lymphatic Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced pancreas cancer successfully treated by using combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2015 |
A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tegafur; Treatment Outcome | 2015 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome; Vomiting | 2015 |
[Efficacy of neoadjuvant chemotherapy for pancreatic carcinoma planned resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
[A case of stage IV b pancreatic head cancer that was resected because of a good response to chemotherapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2015 |
Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
[Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2015 |
[The progress of chemotherapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
A Rare Pancreatic Tumor That Underwent a Change in Morphology and Histopathologic Features During Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Acinar Cell; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2016 |
[Long Term Survival in a Case of Hilar Cholangiocarcinoma Treated with Chemotherapy and Surgery].
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Male; Oxonic Acid; Pancreatectomy; Tegafur; Time Factors; Treatment Outcome | 2015 |
[A Patient with Three-Year Relapse-Free Survival after Surgical Resection for Lung and Liver Metastases of Cholangiocarcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Recurrence; Tegafur | 2015 |
[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Recurrence; Tegafur | 2015 |
[R0 Resection of Locally Advanced Pancreatic Cancer after Combination Chemotherapy with Gemcitabine and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Surgical Resection after Chemotherapy for Ampullary Carcinoma with Synchronous Liver Metastasis--Report of a Case].
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Duodenal Neoplasms; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2015 |
[A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Adjuvant Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer following Gemcitabine and S-1 Chemotherapy--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Tegafur; Treatment Outcome | 2015 |
[A Case of Radical Resection for Locally Advanced Pancreatic Cancer with Positive Peritoneal Cytology Treated with Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Two Cases of Liver Metastasis from Pancreatic Cancer with a Complete Response Owing to Chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Drug Combinations; Duodenum; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach; Tegafur | 2015 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays | 2016 |
Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-19-9 Antigen; Chemoradiotherapy; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Tomography, X-Ray Computed | 2016 |
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Drug Combinations; Female; Gemcitabine; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome; Zoledronic Acid | 2016 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hospitals, University; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Precision Medicine; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Tegafur | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Tegafur; Treatment Outcome | 2017 |
Raising the bar for the adjuvant treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Ductal; Deoxycytidine; Female; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
Expression of Bcl-2 19-kDa interacting protein 3 predicts prognosis after ampullary carcinoma resection.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Biliary Tract Surgical Procedures; Biomarkers, Tumor; Biopsy, Needle; Chemotherapy, Adjuvant; Cohort Studies; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Genes, bcl-2; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Rare Diseases; Retrospective Studies; Risk Assessment; Survival Analysis; Tegafur; Thymidylate Synthase | 2016 |
[Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma: Report of a Case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Reoperation; Survival; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period; Radiotherapy Dosage; Retrospective Studies; Tegafur | 2017 |
Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2017 |
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Young Adult | 2017 |
[Long-Term Survival after Locally Advanced Pancreatic Ductal Adenocarcinoma Treated with Multidisciplinary Therapy - A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Humans; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer with Hepatic Arterial Variation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2016 |
[A Case of Locally Advanced Gallbladder Cancer That Developed Early Multiple Liver Metastasis after Curative Resection, and Achieved Long-TermPartial Remission Using S-1 and Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2016 |
[Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
[A Case of Lymph Node Metastasis of Intrahepatic Bile Duct Cancer Successfully Treated Using Multidisciplinary Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Recurrence; Tegafur; Treatment Outcome | 2016 |
Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
Topics: Abdominal Abscess; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Laparotomy; Lymph Node Excision; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pancreatic Fistula; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Time-to-Treatment | 2017 |
Clinical impact of circulating tumor cells and therapy response in pancreatic cancer.
Topics: Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Multivariate Analysis; Neoplasm Staging; Neoplastic Cells, Circulating; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2017 |
Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Regional Blood Flow; Retrospective Studies; Survival Analysis; Tegafur | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Thrombocytopenia; Vomiting | 2017 |
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Chemoradiotherapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thymidylate Synthase | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Renal Insufficiency; Tegafur | 2017 |
Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2017 |
A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy: Does it work or induce endocrine differentiation?
Topics: Aged; Antineoplastic Agents; Carcinoma, Acinar Cell; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Osteonectin; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
[Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors | 2017 |
[Long-Term Survival after Multidisciplinary Treatment for Resected Pancreatic Adenocarcinoma with Recurrence of Pulmonary Metastases - A Case Report].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Paclitaxel; Pancreaticoduodenectomy; Pneumonectomy; Recurrence; Tegafur; Time Factors | 2017 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2018 |
Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
[A Resected Case of Long-Term Survival of Pancreatic Cancer with Simultaneous Multiple Lung Metastasis with Systemic Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Time Factors | 2018 |
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cytoplasm; Deoxycytidine; Disease-Free Survival; Drug Combinations; ELAV-Like Protein 1; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pyridines; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2018 |
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Proportional Hazards Models; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Risk Factors; Survival Rate; Tegafur | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafur | 2018 |
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
[Two Case Reports of Chemotherapy-Induced Radiation Myositis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Myositis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2018 |
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2018 |
Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Tegafur | 2019 |
Gemcitabine plus S-1 for metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2018 |
Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Plastic Surgery Procedures; Pyridines; Recurrence; Tegafur | 2019 |
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Weight Loss | 2019 |
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Choice Behavior; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Predictive Value of Tests; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Uracil | 2019 |
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Diseases; Liver Neoplasms; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Tegafur; Tomography, X-Ray Computed | 2019 |
Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Models, Theoretical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2019 |
Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Platelet Activation; Platelet Glycoprotein GPIb-IX Complex; Tegafur | 2019 |
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Tegafur | 2020 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Reproducibility of Results; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microwaves; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2021 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Taiwan; Tegafur; Treatment Failure | 2020 |
The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Sarcopenia; Tegafur; Treatment Outcome | 2021 |
Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tegafur; Treatment Outcome | 2021 |
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur | 2021 |
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nutrition Assessment; Nutrition Therapy; Nutritional Status; Oxonic Acid; Pancreatic Neoplasms; Phytotherapy; Polysaccharides; Shiitake Mushrooms; Tegafur; Treatment Outcome | 2021 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peripheral Nerves; Retrospective Studies; Survival Rate; Tegafur | 2021 |
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Propensity Score; Survival Rate; Tegafur | 2021 |
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nomograms; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Probability; Proportional Hazards Models; ROC Curve; Sex Factors; Survival Rate; Tegafur | 2021 |
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2022 |
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2022 |
[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine].
Topics: Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans; Oxonic Acid; Prognosis; Pyridines; Recurrence; Retrospective Studies; Tegafur | 2022 |